Product Reports Resources Pricing Login Book a demo

Capstan Therapeutics

Biotech & Life Sciences · San Diego, United States · Founded 2021

CapstanTX is a biotechnology startup that specializes in developing targeted lipid nanoparticles (tLNPs). These are tiny particles that can be loaded with medical payloads, such as mRNA or gene editing tools, and then delivered to specific cells in the body. This technology is designed to reprogram specific cell types, potentially treating a range of diseases at their source. The company's tLNPs can be adjusted to meet safety and efficacy standards for different diseases, and they can potentially be administered in earlier disease stages and in outpatient settings. The company's technology is modular, meaning it can be adapted to deliver a wide range of payloads. For example, it can deliver mRNA-encoded CARs (Chimeric Antigen Receptors) to specific immune cells, programming them to eliminate disease-causing cells. It can also deliver gene editing tools to pathogenic cells, modifying their DNA to treat genetic diseases. CapstanTX operates in the biotechnology market, serving clients in the medical and pharmaceutical industries. The company makes money by developing and licensing its technology to these clients. The team at CapstanTX is made up of scientific leaders from various fields, including cell and gene therapy, RNA and delivery technologies, and drug development. They are committed to pioneering new medical treatments to improve market access and scalability, and to increase the range of therapeutic options available to patients. Keywords: Biotechnology, Targeted Lipid Nanoparticles (tLNPs), mRNA, Gene Editing, Disease Treatment, Modular Technology, Medical Payloads, Pharmaceutical Industry, Cell Reprogramming, Genetic Diseases.

Investors

21 investors on Capstan Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 4 investors entered at this stage
OrbiMed
RA Capital Management
Novartis Venture Fund
Vida Ventures
Series A 11 investors entered at this stage
Pfizer Ventures
Eli Lilly
Polaris Partners
Bristol-Myers Squibb
Alexandria Venture Investments
Leaps by Bayer
Sofinnova Investments
Forbion Capital Partners
Johnson & Johnson Innovation
Perceptive Advisors
Mubadala Capital
Series B+ 6 investors entered at this stage
Perceptive Advisors
Forbion Capital Partners
University of Pennsylvania
Johnson & Johnson Innovation
Mubadala Capital
Sofinnova Investments

Global footprint

Where Capstan Therapeutics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States95.8%
🇳🇱 Netherlands4.2%
2 countries shown
Web traffic by country
230 monthly visits
across markets
🇺🇸 United States87%
Top 1 markets shown

Talent graph

The shape of Capstan Therapeutics's talent

Dealroom maps Capstan Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

22 team members profilednamed & role-tagged by Dealroom
24 employeestotal headcount
11 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Capstan Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$173k patent portfolio · 6 active families

Estimated portfolio value
$173k
<0.01% of valuation · 958.5× smaller than top peer Lexicon Pharmaceuticals ($166M)
6 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Capstan Therapeutics

An AI-synthesized read of the highest-engagement posts about Capstan Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Capstan Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.